111371-30-3

Basic information

• Product Name: 1H-Thieno(3,4-d)imidazole, 2-(((5-methyl-2-pyridinyl)methyl)sulfinyl)-
• Synonyms: 1H-Thieno(3,4-d)imidazole, 2-(((5-methyl-2-pyridinyl)methyl)sulfinyl)-;S 1924;2-[[(5-Methyl-2-pyridinyl)methyl]sulfinyl]-1H-thieno[3,4-d]imidazole
• CAS NO: 111371-30-3
• Molecular Formula: C12H11 N3 O S2
• Molecular Weight: 277.37
• Mol File: 111371-30-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 565.7°C at 760 mmHg
• Flash Point: 295.9°C
• Appearance: /
• Density: 1.51g/cm³
• Vapor Pressure: 8.14E-13mmHg at 25°C
• Refractive Index: 1.756
• CAS DataBase Reference: 1H-Thieno(3,4-d)imidazole, 2-(((5-methyl-2-pyridinyl)methyl)sulfinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Thieno(3,4-d)imidazole, 2-(((5-methyl-2-pyridinyl)methyl)sulfinyl)-(111371-30-3)
• EPA Substance Registry System: 1H-Thieno(3,4-d)imidazole, 2-(((5-methyl-2-pyridinyl)methyl)sulfinyl)-(111371-30-3)

Safety Data

• Hazardous Substances Data: 111371-30-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H11N3OS2/c1-8-2-3-9(13-4-8)7-18(16)12-14-10-5-17-6-11(10)15-12/h2-6H,7H2,1H3,(H,14,15)

Upstream product

• 111371-68-7 2-(5-Methyl-pyridin-2-ylmethylsulfanyl)-1H-thieno[3,4-d]imidazole; hydrobromide 

Relevant articles and documents

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.